Results 51 to 60 of about 18,010 (199)

209. Population Pharmacokinetics of Meropenem-Vaborbactam in Acutely Ill Hospitalized Patients with Various Degrees of Renal Dysfunction [PDF]

Open Forum Infect Dis
Griffin Reed, Adrian Valadez, Erin K McCreary, Ellen G Kline, Brandon Smith, Michael Neely, Kevin M Squires, Ryan K. Shields, Nathaniel J. Rhodes   +8 more
europepmc   +3 more sources

P-1499. Patient Characteristics and Clinical Outcomes Associated with Meropenem/Vaborbactam Treatment in Carbapenem-Resistant Enterobacterales Pneumonia [PDF]

Open Forum Infect Dis
Kaylee E Caniff, Chloe Judd, Taryn A Eubank, Kevin W. Garey, Tamara Krekel, Wesley D. Kufel, Justin Andrade, John Cerenzio, Michael P. Veve, Michael J. Rybak   +9 more
europepmc   +3 more sources

Comparative Outcomes of Meropenem-Vaborbactam vs. Ceftazidime-Avibactam Among Adults Hospitalized with an Infectious Syndrome in the US, 2019-2021. [PDF]

Antibiotics (Basel)
Zilberberg MD, Nathanson BH, Redell MA, Sulham K, Shorr AF.   +4 more
europepmc   +3 more sources

Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections

International Journal of Infectious Diseases, 2021
Background: The limited armamentarium against multidrug-resistant Gram-negative bacilli led to the development of a new generation of β-lactam/β-lactamase inhibitor combinations (BL/BLI).
Helio S. Sader, Mariana Castanheira, Leonard R. Duncan, Rodrigo E. Mendes   +3 more
doaj   +1 more source

New evidence in severe pneumonia: meropenem-vaborbactam

Revista Española de Quimioterapia, 2022
The appearance and spread of new mechanisms of bacterial resistance to antibiotics is a serious health problem. One of the most difficult resistance mechanisms to treat is the production of carbapenemases. Carbapenemase KPC is one of those mechanisms with few therapeutic options.
Forteza Guillot, Maria, Martin Cerezuela, Maria, Ramirez, Paula   +2 more
openaire   +3 more sources

The European Medicines Agency Approved the New Antibacterial Drugs – Response to the 2017 Who Report on the Global Problem of Multi-Drug Resistance

Postępy Mikrobiologii, 2021
The growing problem of antimicrobial resistance has been classified by the World Health Organization (WHO) as one of the top ten threats to mankind. In a special report published in 2017, the WHO presented a list of microorganisms for which the search ...
Krajewska Joanna, Laudy Agnieszka Ewa
doaj   +1 more source

A Post-Neurosurgical Infection due to KPC-Producing Klebsiella pneumoniae Treated with Meropenem-Vaborbactam: A Case Report

International Journal of Infectious Diseases, 2022
This case report describes a patient with post-neurosurgical infection and bacteremia caused by Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae.
Seohyun Choi, Marianna Fedorenko, Janet Lin-Torre, Nirav Mistry, Steven Smoke   +4 more
doaj   +1 more source

Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations [PDF]

Clinical Infectious Diseases, 2018
Ceftazidime/avibactam and meropenem/vaborbactam are changing the management of invasive infections due to carbapenem-resistant Enterobacteriaceae (CRE), leading to higher rates of clinical cure, decreased mortality, and decreased rates of acute kidney injury compared with colistin-based regimens.
Jason M, Pogue, Robert A, Bonomo, Keith S, Kaye   +2 more
openaire   +2 more sources

Stability Studies of Antipseudomonal Beta Lactam Agents for Outpatient Therapy

Pharmaceutics, 2023
Outpatient parenteral antimicrobial therapy (OPAT) is a useful treatment strategy against Pseudomonas aeruginosa and other multidrug-resistant bacteria.
Beatriz Fernández-Rubio, Laura Herrera-Hidalgo, Arístides de Alarcón, Rafael Luque-Márquez, Luis E. López-Cortés, Sònia Luque, José María Gutiérrez-Urbón, Aurora Fernández-Polo, Alicia Gutiérrez-Valencia, María V. Gil-Navarro   +9 more
doaj   +1 more source

Aggressive joint pharmacokinetic/pharmacodynamic target attainment of TDM-guided continuous infusion meropenem-vaborbactam monotherapy: A valuable strategy for maximizing the microbiological outcome of documented KPC-producing Enterobacterales infections?

Objective: To assess whether attaining an aggressive joint pharmacokinetic/pharmacodynamic (PK/PD) target of therapeutic drug monitoring (TDM)-guided continuous infusion (CI) meropenem-vaborbactam monotherapy may be a valuable strategy for maximizing the
Milo Gatti, Cecilia Bonazzetti, Benedetta Secci, Beatrice Giorgi, Matteo Rinaldi, Pier Giorgio Cojutti, Simone Ambretti, Antonio Siniscalchi, Tommaso Tonetti, Pierluigi Viale, Federico Pea   +10 more
openalex   +2 more sources